Tag: prostate cancer

1. Magnetic resonance imaging with targeted and standard biopsy was non-inferior for the detection of clinically significant cancers compared to standard biopsy only. 2. The detection of clinically insignificant cancers was less in the MRI group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer screening reduces prostate cancer mortality but has high...
1. Magnetic resonance imaging with targeted and standard biopsy was non-inferior for the detection of clinically significant cancers compared to standard biopsy only. 2. The detection of clinically insignificant cancers was less in the MRI group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer screening reduces prostate cancer mortality but has...
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 or greater adverse events occurred in 70% of patients treated with ipatasertib plus abiraterone versus 39% in placebo plus abiraterone. Evidence Rating Level: 1 (Excellent) Study Rundown: Metastatic castration-resistant prostate cancer (mCRPC) is currently...
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 or greater adverse events occurred in 70% of patients treated with ipatasertib plus abiraterone versus 39% in placebo plus abiraterone. Evidence Rating Level: 1 (Excellent) Study Rundown: Metastatic castration-resistant prostate cancer...
1. Among patients with high-risk prostate cancer receiving guideline-concordant multimodal therapy, prostate cancer-specific mortality outcomes were equivalent among radical prostatectomy, external beam radiotherapy alone, and external beam radiotherapy plus brachytherapy. 2. Novel treatment and research strategies should be focused on minimizing distant metastasis in patients with high-risk prostate cancer, particularly...
1. 3-year event-free survival rates were significantly greater in the 18F-fluciclovine-PET group compared to conventional imaging. 2. Adverse reactions and toxicity levels were similar between the two groups. Evidence Rating Level: 1 (Excellent) Study Rundown: In patients with prostate cancer, prostatectomies are often followed with adjuvant or salvage radiotherapy. Postprostatectomy radiotherapy has...
1. Radiolabeled Lutetium-177 offered greater PSA response versus current standard of care, cabazitaxel. 2. Fewer grade 3-4 adverse events occurred in patients treated with Lutetium-177 compared to cabazitaxel. Evidence Rating Level: 1 (Excellent) Study Rundown: Although metastatic castration-resistant prostate cancer (mCRPC) is incurable, there exists several treatment options known to prolong overall...
1. The use of long-term transdermal estrogen for castration therapy for prostate cancer showed no difference in cardiovascular events versus current standard of care. 2. Gynecomastia was significantly more common in the transdermal estrogen group than standard of care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer, an ongoing major...
1. Adjuvant radiotherapy was found to increase the risk of urinary incontinence and urethral strictures compared to salvage radiotherapy in patients with prostate cancer. 2. Adjuvant radiotherapy did not show any benefit in biochemical control or time to hormone therapy following radical prostatectomy, compared to salvage radiotherapy. Evidence Rating Level: 1...
1. Adjuvant radiotherapy was found to increase the risk of urinary incontinence and urethral strictures compared to salvage radiotherapy in patients with prostate cancer. 2. Adjuvant radiotherapy did not show any benefit in biochemical control or time to hormone therapy following radical prostatectomy, compared to salvage radiotherapy. Evidence Rating Level: 1...